| 2026-08-24 | Press release | Oruka Therapeutics Appoints Todd Edwards as Chief Commercial Officer |
| 2026-08-24 | Press release | Oruka Therapeutics Appoints Todd Edwards as Chief Commercial Officer |
| 2026-08-24 | 8-K | Form 8-K, Item 5.02 |
| 2026-08-10 | Deck | Corporate Presentation |
| 2026-08-10 | Press release | Oruka Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update |
| 2026-08-10 | 8-K | Form 8-K, Item 2.02 results |
| 2026-08-10 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2026-06-23 | Press release | PDF Version |
| 2026-06-04 | 8-K | Form 8-K, Item 5.07 |
| 2026-06-01 | 8-K | Form 8-K, Item 8.01 |
| 2026-05-28 | Press release | Oruka Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference |
| 2026-05-13 | Press release | Oruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update |
| 2026-05-13 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2026-05-06 | Press release | Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology |
| 2026-04-30 | 8-K | Form 8-K, Item 2.02 results |
| 2026-04-28 | Press release | Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public Offering |
| 2026-04-27 | Deck | Interim EVERLAST-A Data Presentation |
| 2026-04-27 | Press release | Oruka Therapeutics Announces Proposed $500 Million Underwritten Public Offering |
| 2026-04-27 | Press release | Oruka Therapeutics Announces Positive Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Phase 2a Trial in Moderate-t |
| 2026-04-27 | Press release | Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Trial on Apri |
| 2026-04-27 | 8-K | Form 8-K, Item 7.01 |
| 2026-04-17 | Proxy | Definitive proxy statement |
| 2026-03-12 | Press release | Oruka Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update |
| 2026-03-12 | 10-K | Annual report on Form 10-K, FY25 |
| 2026-02-09 | Press release | Oruka Therapeutics to Participate in Multiple Upcoming Conferences |
| 2026-01-12 | Press release | PDF Version |
| 2026-01-06 | Press release | PDF Version |
| 2026-01-06 | Press release | Oruka Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference |
| 2025-12-11 | 8-K | Form 8-K, Item 5.02 |
| 2025-11-12 | 10-Q | Form 10-Q for the quarter ended Sep 30 |
| 2025-09-22 | 8-K | Form 8-K, Item 1.01 |
| 2025-08-11 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2025-07-01 | 8-K | Form 8-K, Item 5.02 |
| 2025-06-03 | 8-K | Form 8-K, Item 5.07 |
| 2025-05-14 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2025-04-18 | Proxy | Definitive proxy statement |
| 2025-03-06 | 10-K | Annual report on Form 10-K, FY24 |
| 2025-02-05 | 8-K | Form 8-K, Item 1.01 |
| 2024-12-19 | 8-K | Form 8-K, Item 1.01 |
| 2024-11-18 | 8-K | Form 8-K, Item 5.07 |